Viridian Therapeutics, Inc./DE Capital Expenditures Incurred but Not yet Paid
Viridian Therapeutics, Inc./DE (VRDN) reported Capital Expenditures Incurred but Not yet Paid of $446.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2026-08-06
- Viridian Therapeutics, Inc./DE capital expenditures incurred but not yet paid for the quarter ending 2025-09-30 was $17.00K, a 72.58% decline year-over-year.
- Viridian Therapeutics, Inc./DE capital expenditures incurred but not yet paid for the quarter ending 2024-12-31 was -$45.00K.
- Viridian Therapeutics, Inc./DE capital expenditures incurred but not yet paid for the quarter ending 2024-09-30 was $62.00K.
- Viridian Therapeutics, Inc./DE capital expenditures incurred but not yet paid for the quarter ending 2024-06-30 was $26.00K, a 10.34% decline year-over-year.
- Viridian Therapeutics, Inc./DE capital expenditures incurred but not yet paid for fiscal 2024 was $43.00K.
- Viridian Therapeutics, Inc./DE capital expenditures incurred but not yet paid for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Viridian Therapeutics, Inc./DE capital expenditures incurred but not yet paid for fiscal 2022 was $380.00K, a 9400.00% increase from fiscal 2021.
- Viridian Therapeutics, Inc./DE capital expenditures incurred but not yet paid for fiscal 2021 was $4.00K.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|
| 2026-06-30 | $446.00K 10-Q · filed 2026-08-06 | |||
| 2025-09-30 | $17.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $17.00K 10-Q · filed 2025-11-05 | ||
| 2025-06-30 | $0.00 10-Q · filed 2026-08-06 | |||
| 2024-12-31 | -$45.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $17.00K derived: sum of 2 quarters · filed 2025-11-05 | $43.00K derived: sum of 3 quarters · filed 2025-11-05 | $43.00K 10-K · filed 2025-03-03 |
| 2024-09-30 | $62.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $88.00K derived: sum of 2 quarters · filed 2025-11-05 | $88.00K 10-Q · filed 2025-11-05 | $63.00K derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $26.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $26.00K 10-Q · filed 2025-08-06 | $1.00K derived: sum of 3 quarters · filed 2025-08-06 | -$288.00K derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-08 | -$25.00K derived: sum of 2 quarters · filed 2025-03-03 | -$314.00K derived: sum of 3 quarters · filed 2025-03-03 | -$285.00K derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-12-31 | -$25.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$314.00K derived: sum of 2 quarters · filed 2025-03-03 | -$285.00K derived: sum of 3 quarters · filed 2025-03-03 | $0.00 10-K · filed 2025-03-03 |
| 2023-09-30 | -$289.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$260.00K derived: sum of 2 quarters · filed 2024-11-12 | $25.00K 10-Q · filed 2024-11-12 | $361.00K derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $29.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $314.00K 10-Q · filed 2024-08-08 | $650.00K derived: sum of 3 quarters · filed 2025-03-03 | $694.00K derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $285.00K 10-Q · filed 2024-05-08 | $621.00K derived: sum of 2 quarters · filed 2025-03-03 | $665.00K derived: sum of 3 quarters · filed 2025-03-03 | $488.00K derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $336.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $380.00K derived: sum of 2 quarters · filed 2025-03-03 | $203.00K derived: sum of 3 quarters · filed 2025-03-03 | $380.00K 10-K · filed 2025-03-03 |
| 2022-09-30 | $44.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$133.00K derived: sum of 2 quarters · filed 2023-11-13 | $44.00K 10-Q · filed 2023-11-13 | $25.00K derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | -$177.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $0.00 10-Q · filed 2023-08-08 | -$19.00K derived: sum of 3 quarters · filed 2024-02-27 | -$116.00K derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $177.00K 10-Q · filed 2023-05-10 | $158.00K derived: sum of 2 quarters · filed 2024-02-27 | $61.00K derived: sum of 3 quarters · filed 2024-02-27 | $181.00K derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | -$19.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | -$116.00K derived: sum of 2 quarters · filed 2024-02-27 | $4.00K derived: sum of 3 quarters · filed 2024-02-27 | $4.00K 10-K · filed 2024-02-27 |
| 2021-09-30 | -$97.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $23.00K derived: sum of 2 quarters · filed 2022-11-14 | $23.00K 10-Q · filed 2022-11-14 | $23.00K derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $120.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $120.00K 10-Q · filed 2022-08-15 | $120.00K derived: sum of 3 quarters · filed 2022-08-15 | $120.00K derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $0.00 10-Q · filed 2022-05-13 | $0.00 derived: sum of 2 quarters · filed 2022-05-13 | $0.00 derived: sum of 3 quarters · filed 2022-05-13 | |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $0.00 derived: sum of 2 quarters · filed 2022-03-11 | $0.00 10-K · filed 2022-03-11 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | $0.00 10-Q · filed 2021-11-05 | ||
| 2020-06-30 | $0.00 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |